Do you have the same question? Follow this Question
Apr 30, 2026 - 08:20 AM
We’ve provided several answers to questions related to Retevmo (Selpercatinib) , see some other helpful Q&A related to this product.
Question: What is the US FDA approval year for this medication?
Answer: This medication was approved by the US FDA in 2020. FDA approval means the medication has been evaluated for safety and effectiveness.
Question: What is the bioavailability of this medication?
Answer: The bioavailability is approximately 73% when taken orally. Bioavailability indicates how much of the drug reaches the bloodstream, which is important for dosing and effectiveness.
Question: What are the available dosage strengths for the capsules?
Answer: The capsules are available in 40 mg and 80 mg strengths. Having multiple dosage options allows healthcare providers to tailor the treatment plan to the patient’s needs.
Question: What is the brand name of the drug?
Answer: The brand name is Retevmo. Brand names help patients and healthcare providers identify medications and ensure the correct product is dispensed.
Question: Does selpercatinib cause hair loss?
Answer: Selpercatinib does not commonly cause hair loss. Hair loss is not listed as a typical side effect of selpercatinib, but if you notice unusual hair changes while taking it, consult your doctor.
